SCHEMBL4060257

SCHEMBL4060257

Fc1ccccc1-c1ccc2nc(-c3cc4ccccc4o3)oc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VSIR Q9H7M9 1/20 0.51
GPR119 Q8TDV5 1/20 0.47
PIK3R1 P27986 1/20 0.44
PIK3CA P42336 1/20 0.44
HDAC6 Q9UBN7 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
KDM4E B2RXH2 2/20 0.43
BACE1 P56817 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
CASP1 P29466 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054476 0.82 VSIR (0.61) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4062955 0.80 VSIR (0.56) VSIRGPR119PIK3R1PIK3CAHDAC6
SCHEMBL4054275 0.78 VSIR (0.63) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4056364 0.78 ALOX5 (0.58) GPR119PIK3R1PIK3CAKDM4ENPC1
SCHEMBL4059650 0.78 VSIR (0.54) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL3132729 0.77 NPC1 (0.61) KDM4ENPC1ALDH1A1TP53GLA
SCHEMBL4053956 0.77 VSIR (0.48) VSIRGPR119PIK3R1PIK3CAHDAC6
SCHEMBL4058059 0.76 VSIR (0.61) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4054281 0.76 NPC1 (0.55) VSIRGPR119HDAC6HDAC3HDAC1
SCHEMBL4054584 0.76 NPC1 (0.61) VSIRGPR119HDAC6HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B VSIR 4618/4885GPR119 1677/4885PIK3R1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.